Amin'S Pathology Laboratory Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 15-11-2024
- Paid Up Capital ₹ 1.00 M
as on 15-11-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 171.33%
(FY 2023)
- Profit 202.53%
(FY 2023)
- Ebitda 131.14%
(FY 2023)
- Net Worth 28.01%
(FY 2023)
- Total Assets 27.72%
(FY 2023)
About Amin'S Pathology Laboratory
The Corporate was formerly known as Metropolis Wellness Products Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Nilesh Shah and Rakesh Agarwal serve as directors at the Company.
- CIN/LLPIN
U52300MH2012PTC236779
- Company No.
236779
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 2012
- Date of AGM
24 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Amin'S Pathology Laboratory?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nilesh Shah  | Director | 02-May-2013 | Current |
| Rakesh Agarwal | Director | 18-Nov-2019 | Current |
Financial Performance and Corporate Structure Insights of Amin'S Pathology Laboratory.
Amin'S Pathology Laboratory Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 171.33% increase. The company also saw a substantial improvement in profitability, with a 202.53% increase in profit. The company's net worth Soared by an impressive increase of 28.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amin'S Pathology Laboratory?
In 2023, Amin'S Pathology Laboratory had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Centre For Digestive And Kidney Diseases (India) Private LimitedActive 20 years 7 monthsRakesh Agarwal is a mutual person
Centralab Healthcare Services Private LimitedActive 13 years 8 monthsRakesh Agarwal is a mutual person
Ekopath Metropolis Lab Services Private LimitedActive 11 years 10 monthsNilesh Shah and Rakesh Agarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Amin'S Pathology Laboratory?
Amin'S Pathology Laboratory has a workforce of 299 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amin'S Pathology Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amin'S Pathology Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
